Why the study?
Does trimetazidine added to ACE inhibitors improve myocardial perfusion and physical performance in patients with arterial hypertension and type 2 diabetes mellitus?
RCT (n=69)
Open-label
Parallel
Does trimetazidine added to ACE inhibitors improve myocardial perfusion and physical performance in patients with arterial hypertension and type 2 diabetes mellitus?
The addition of trimetazidine to ACE inhibitors improves myocardial perfusion and exercise tolerance in patients with arterial hypertension and type 2 diabetes mellitus.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Карпов et al. (2006) conducted an RCT in Arterial hypertension and type 2 diabetes mellitus (with or without ischemic heart disease) (n=69). Preductal (trimetazidine) vs. ACE inhibitors alone was evaluated on Size of myocardial perfusion defects on stress scintigrams.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: